Literature DB >> 23296166

Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive.

Rury R Holman1.   

Abstract

Worldwide, >366 million people with type 2 diabetes mellitus remain at excess risk of cardiovascular disease and face a lifetime of treatment escalation for this progressive disorder. Studies in 2012 have re-affirmed the safety of early insulin treatment, metformin use in renal impairment, and shown β-cell function preservation over several years.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296166     DOI： 10.1038/nrendo.2012.243

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  9 in total

1.  Does diabetes therapy influence the risk of cancer?

Authors:  U Smith; E A M Gale
Journal:  Diabetologia       Date:  2009-09       Impact factor: 10.122

Review 2.  Metformin.

Authors:  C J Bailey; R C Turner
Journal:  N Engl J Med       Date:  1996-02-29       Impact factor: 91.245

3.  Basal insulin and cardiovascular and other outcomes in dysglycemia.

Authors:  Hertzel C Gerstein; Jackie Bosch; Gilles R Dagenais; Rafael Díaz; Hyejung Jung; Aldo P Maggioni; Janice Pogue; Jeffrey Probstfield; Ambady Ramachandran; Matthew C Riddle; Lars E Rydén; Salim Yusuf
Journal:  N Engl J Med       Date:  2012-06-11       Impact factor: 91.245

4.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

5.  Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Authors:  C Abraira; J A Colwell; F Q Nuttall; C T Sawin; N J Nagel; J P Comstock; N V Emanuele; S R Levin; W Henderson; H S Lee
Journal:  Diabetes Care       Date:  1995-08       Impact factor: 19.112

6.  β-cell function preservation after 3.5 years of intensive diabetes therapy.

Authors:  Lindsay B Harrison; Beverley Adams-Huet; Philip Raskin; Ildiko Lingvay
Journal:  Diabetes Care       Date:  2012-07       Impact factor: 19.112

Review 7.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

8.  Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.

Authors:  Nils Ekström; Linus Schiöler; Ann-Marie Svensson; Katarina Eeg-Olofsson; Junmei Miao Jonasson; Björn Zethelius; Jan Cederholm; Björn Eliasson; Soffia Gudbjörnsdottir
Journal:  BMJ Open       Date:  2012-07-13       Impact factor: 2.692

9.  Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

Authors:  David M Nathan; John B Buse; Steven E Kahn; Heidi Krause-Steinrauf; Mary E Larkin; Myrlene Staten; Deborah Wexler; John M Lachin
Journal:  Diabetes Care       Date:  2013-05-20       Impact factor: 19.112
  9 in total
  7 in total

Review 1.  An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides.

Authors:  Jiang Cheng; Zhi-Wei Zhou; Hui-Ping Sheng; Lan-Jie He; Xue-Wen Fan; Zhi-Xu He; Tao Sun; Xueji Zhang; Ruan Jin Zhao; Ling Gu; Chuanhai Cao; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

2.  Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches.

Authors:  Zhenzhong Yang; Linli Wang; Feng Zhang; Zheng Li
Journal:  BMC Complement Altern Med       Date:  2015-08-13       Impact factor: 3.659

3.  Consumption of clarified grapefruit juice ameliorates high-fat diet induced insulin resistance and weight gain in mice.

Authors:  Rostislav Chudnovskiy; Airlia Thompson; Kevin Tharp; Marc Hellerstein; Joseph L Napoli; Andreas Stahl
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

4.  Lactobacillus casei reduces susceptibility to type 2 diabetes via microbiota-mediated body chloride ion influx.

Authors:  Yong Zhang; Xiao Guo; Jianlin Guo; Qiuwen He; He Li; Yuqin Song; Heping Zhang
Journal:  Sci Rep       Date:  2014-07-18       Impact factor: 4.379

5.  Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy.

Authors:  Ajith Munasinghe Dissanayake; Mark Christopher Wheldon; Jafar Ahmed; Christopher John Hood
Journal:  Kidney Int Rep       Date:  2017-03-29

6.  Appropriate Insulin Level in Selecting Fortified Diet-Fed, Streptozotocin-Treated Rat Model of Type 2 Diabetes for Anti-Diabetic Studies.

Authors:  Stanley Irobekhian Reuben Okoduwa; Ismaila A Umar; Dorcas B James; Hajiya M Inuwa
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

Review 7.  The PI3K/AKT pathway in obesity and type 2 diabetes.

Authors:  Xingjun Huang; Guihua Liu; Jiao Guo; Zhengquan Su
Journal:  Int J Biol Sci       Date:  2018-08-06       Impact factor: 6.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.